GSK PLC Sponsored ADR

GSK Healthcare Drug Manufacturers General

GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024. In the quarter to June 2026, revenue grew 5.81%, EPS fell 69.5%, free cash flow grew 54.8% and total debt rose 5.61%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

49.55 0.53 +1.08%
Market cap
$98.2B
P/E
15.4×
Fwd P/E
12.4×
Dividend yield
3.67%
F-score
9/9
Altman Z
2.12
Beneish M
−2.46
Dividend safety
54/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

37.41% 39.92% 38.52% 30.74%
Piotroski F-Score
8 9 8 8
ROA
9.16% 9.63% 9.72% 8.01%
ROIC
15.28% 16.44% 15.14% 12.58%
Return on Tangible Assets
91.88% 105.05% 124.42% 89.82%
Average Days of Receivables
97.18 86.69 88.94 88.86
Free Cash Flow per Share
3.19 3.19 3.25 3.81
Free Cash Flow
6,440.71 6,455.04 6,540.67 7,647.98
Other line items

Show all line items

Columns are period end dates